About Ischemix
Ischemix is a company based in Grafton (United States) founded in 2006.. Ischemix has raised $6.6 million across 2 funding rounds from investors including U.S Army. Ischemix offers products and services including CMX-2043. Ischemix operates in a competitive market with competitors including Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Proniras, among others.
- Headquarter Grafton, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ischemix, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.6 M (USD)
in 2 rounds
-
Latest Funding Round
$2.9 M (USD), Grant
Jul 07, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ischemix
Ischemix offers a comprehensive portfolio of products and services, including CMX-2043. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Cytoprotective drug for treating traumatic brain injury effectively.
Funding Insights of Ischemix
Ischemix has successfully raised a total of $6.6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $2.9 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $2.9M
-
First Round
First Round
(05 Jun 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Grant - Ischemix | Valuation |
investors |
|
| Jun, 2014 | Amount | Series A - Ischemix | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ischemix
Ischemix has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include U.S Army. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Land-based military forces are organized and deployed for national defense.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ischemix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ischemix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ischemix Comparisons
Competitors of Ischemix
Ischemix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Edge Therapeutics, veriNOS pharmaceuticals, Neuraptive and Proniras, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Next-generation medicines for CNS and immunological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Novel therapies for acute neurological conditions are developed and commercialized.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for retina and brain diseases
|
|
| domain | founded_year | HQ Location |
Therapeutic solution for the repair of cut and crushed peripheral nerves.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for seizures and brain injury treatment.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ischemix
Frequently Asked Questions about Ischemix
When was Ischemix founded?
Ischemix was founded in 2006 and raised its 1st funding round 8 years after it was founded.
Where is Ischemix located?
Ischemix is headquartered in Grafton, United States.
Is Ischemix a funded company?
Ischemix is a funded company, having raised a total of $6.6M across 2 funding rounds to date. The company's 1st funding round was a Series A of $6.6M, raised on Jun 05, 2014.
What does Ischemix do?
Ischemix was founded in 2006 and is based in Grafton, United States. Focus is placed on the biotechnology sector, where cytoprotective therapies for serious neurological conditions, including traumatic brain injury, are advanced. The lead candidate, CMX-2043, remains in preclinical trials, with activation of protein kinase B achieved through the phosphatidylinositide 3-kinase pathway to support treatment development.
Who are the top competitors of Ischemix?
Ischemix's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
What products or services does Ischemix offer?
Ischemix offers CMX-2043.
Who are Ischemix's investors?
Ischemix has 1 investor. Key investors include U.S Army.